U-AZN

Q:AZN - ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS - http://www.astrazeneca.com

08:14:42 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
AZN - Q	0.9	68.91	·	68.96	1.2	67.83			123.2	2,712	71		76.56 52.65	07:57:25	Sep 22	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 71

More trades...

Time ET	Ex	Price	Change	Volume
07:57:25	Q	68.94	1.11	200
07:49:51	Q	68.94	1.11	200
07:44:40	Q	68.93	1.10	200
07:34:20	Q	68.92	1.09	900
07:32:12	Q	68.92	1.09	200
07:31:12	Q	68.93	1.10	200
07:27:38	Q	68.93	1.10	900
07:27:38	Q	68.93	1.10	200
07:27:38	Q	68.92	1.09	900
07:27:38	Q	68.92	1.09	200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-09-22 07:00	U:AZN	News Release200	Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2023-09-14 02:00	U:AZN	News Release200	AstraZeneca advances UK clean heat and energy efficiencies with ‚ £100m commitment
2023-09-11 12:58	U:AZN	News Release200	FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
2023-09-11 07:05	U:AZN	News Release200	TAGRISSO ‚ ® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
2023-09-11 07:00	U:AZN	News Release200	ENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial

Date ET

Symbol

Type

Headline

2023-09-22 07:00

U:AZN

News Release

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

2023-09-14 02:00

U:AZN

News Release

AstraZeneca advances UK clean heat and energy efficiencies with ‚ £100m commitment